articleTop 1% cited
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
The Lancet Oncology · 2014 · Vol. 15(11) · pp. 1224–1235
H. Wilke✉(University of Duisburg-Essen)Kei Muro(Aichi Cancer Center)Eric Van Cutsem(KU Leuven)Sang-Cheul Oh(Korea University Medical Center)G. Bodoky(Unified Szent István and Szent László Hospital)Yasuhiro Shimada(Tokyo National Hospital)Shuichi Hironaka(Chiba Cancer Center)Naotoshi Sugimoto(Osaka International Cancer Institute)Oleg Lipatov(Republican Oncological Clinical Dispensary)Tae‐You Kim(Seoul National University Hospital)David Cunningham(Royal Marsden Hospital)Philippe Rougier(Université Paris Cité)Yoshito Komatsu(Hokkaido University)Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center)Michael Emig(Eli Lilly (Germany))Roberto Carlesi(Eli Lilly (Italy))David Ferry(New Cross Hospital)Kumari Chandrawansa(Eli Lilly (United States))Jonathan D. SchwartzAtsushi Ohtsu(National Cancer Center Hospital East)
Gastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentGastrointestinal Tumor Research and TreatmentRamucirumabMedicinePlaceboPaclitaxelInternal medicineClinical endpointCancerGastroenterologyChemotherapySurgery
MeSH terms
RamucirumabAdenocarcinomaAdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansMaleMiddle Aged
Funding
- Eli Lilly and Company
- AstraZeneca
- National Institute for Health and Care Research
- National Institutes of Health
- Eli Lilly Japan
Citations
2,435
FWCI
137.62
field-weighted impact
References
35
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Cancers · 2016 · 590 citations
Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies
International Journal of Molecular Sciences · 2020 · 1,524 citations
Chemotherapy for advanced gastric cancer
Cochrane Database of Systematic Reviews · 2017 · 1,287 citations
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
European Heart Journal · 2016 · 2,487 citations
Advanced gastric cancer: Current treatment landscape and future perspectives
World Journal of Gastroenterology · 2016 · 577 citations
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Cancer Cell · 2014 · 1,503 citations
Biomarkers of gastric cancer: Current topics and future perspective
World Journal of Gastroenterology · 2018 · 496 citations
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 1,581 citations
References
Interpreting the significance of changes in health-related quality-of-life scores.
Journal of Clinical Oncology · 1998 · 2,890 citations
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
International Journal of Cancer · 2010 · 21,378 citations
Modeling Valuations for EuroQol Health States
Medical Care · 1997 · 4,548 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
The Lancet · 2010 · 7,196 citations
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
European Journal of Cancer · 2011 · 611 citations
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
New England Journal of Medicine · 2004 · 10,930 citations
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
JNCI Journal of the National Cancer Institute · 1993 · 15,705 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.